Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | CLK1 | P49759 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23103530 | 0.85 | CYP1A2 (0.50) | CYP1A2CYP2C9KDM4EGAAGLA | |
| SCHEMBL18357556 | 0.76 | CYP1A2 (0.47) | CYP1A2CYP2C9KDM4EGAAGLA | |
| SCHEMBL13976120 | 0.74 | LMNA (0.39) | CYP1A2CYP2C9POLBSMN1; SMN2TGFBR1 | |
| SCHEMBL20903418 | 0.73 | CYP1A2 (0.45) | CYP1A2CYP2C9KDM4EGAAGLA | |
| SCHEMBL16946872 | 0.73 | CYP1A2 (0.45) | CYP1A2CYP2C9KDM4EGAAGLA | |
| SCHEMBL17338963 | 0.73 | PIK3CA (0.43) | CYP1A2CYP2C9GAAALDH1A1TGFBR1 | |
| SCHEMBL24087021 | 0.73 | TGFBR1 (0.43) | KDM4ETGFBR1 | |
| SCHEMBL20778278 | 0.73 | POLB (0.51) | GAAALDH1A1POLBCLK1 | |
| SCHEMBL24919893 | 0.73 | TGFBR1 (0.33) | CYP1A2CYP2C9POLBTGFBR1 | |
| SCHEMBL25526880 | 0.73 | CYP1A2 (0.49) | CYP1A2CYP2C9KDM4EGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | CYP1A2 4482/4885CYP2C9 4221/4885KDM4E 1402/4885 |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | CYP1A2 4482/4885CYP2C9 4221/4885KDM4E 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.